Springer Seminars in Immunopathology

, Volume 28, Issue 4, pp 383–395 | Cite as

IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential

Review
First Online:
Received:
Accepted:

Abstract

IgA antibodies play an important role in humoral immunity. IgA is the predominant antibody in mucosal secretions and the second most prevalent in the serum. It occupies a unique position among human antibodies in that it can both trigger and suppress inflammatory responses, depending on the situation. Recent structural and functional studies have revealed details of the structure of IgA and its interaction with key cell-surface receptors. We look at the role IgA and IgA receptors (particularly FcαRI) play in the pathogenesis of diseases such as IgA nephropathy and other autoimmune conditions. Finally, we address the potential of IgA as a therapeutic tool to either trigger specific inflammatory responses to destroy target cells or suppress inflammatory responses in the case of autoimmune diseases, and the promise of mucosal vaccines for eliciting specific IgA responses to pathogens in mucosal environments.

Keywords

FcαRI pIgR TfR IgA nephropathy X-ray crystallography 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Monteiro RC, van de Winkel JG (2003) IgA Fc receptors. Annu Rev Immunol 177–204Google Scholar
  2. 2.
    Norderhaug IN, Johansen FE, Schjerven H, Brandtzaeg P (1999) Regulation of the formation and external transport of secretory immunoglobulins. Crit Rev Immunol 19:481–508PubMedGoogle Scholar
  3. 3.
    van Egmond M, van Garderen E, van Spriel AB, Damen CA, van Amersfoort ES, van Zandbergen G, van Hattum J, Kuiper J, van de Winkel JG (2000) FcaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 6:680–685PubMedGoogle Scholar
  4. 4.
    Vidarsson G, van Der Pol WL, van Den Elsen JM, Vile H, Jansen M, Duijs J, Morton HC, Boel E, Daha MR, Corthesy B, van De Winkel JG (2001) Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 166:6250–6256PubMedGoogle Scholar
  5. 5.
    Monteiro RC, Kubagawa H, Cooper MD (1990) Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med 171:597–613PubMedGoogle Scholar
  6. 6.
    Shibuya A, Sakamoto N, Shimizu Y, Shibuya K, Osawa M, Hiroyama T, Eyre HJ, Sutherland GR, Endo Y, Fujita T, Miyabayashi T, Sakano S, Tsuji T, Nakayama E, Phillips JH, Lanier LL, Nakauchi H (2000) Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol 1:441–446PubMedGoogle Scholar
  7. 7.
    Boehm MK, Woof JM, Kerr MA, Perkins SJ (1999) The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 286:1421–1447PubMedGoogle Scholar
  8. 8.
    Keown MB, Ghirlando R, Young RJ, Beavil AJ, Owens RJ, Perkins SJ, Sutton BJ, Gould HJ (1995) Hydrodynamic studies of a complex between the Fc fragment of human IgE and a soluble fragment of the Fc epsilon RI alpha chain. Proc Natl Acad Sci USA 92:1841–1845PubMedGoogle Scholar
  9. 9.
    Herr AB, Ballister ER, Bjorkman PJ (2003) Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature 423:614–620PubMedGoogle Scholar
  10. 10.
    Mostov KE (1994) Transepithelial transport of immunoglobulins. Annu Rev Immunol 12:63–84PubMedGoogle Scholar
  11. 11.
    Maliszewski CR, March CJ, Schoenborn MA, Gimpel S, Shen L (1990) Expression cloning of a human Fc receptor for IgA. J Exp Med 172:1665–1672PubMedGoogle Scholar
  12. 12.
    Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC (2001) Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194:417–425PubMedGoogle Scholar
  13. 13.
    Lamkhioued B, Gounni AS, Gruart V, Pierce A, Capron A, Capron M (1995) Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation. Eur J Immunol 25:117–125PubMedGoogle Scholar
  14. 14.
    Mantis NJ, Cheung MC, Chintalacharuvu KR, Rey J, Corthesy B, Neutra MR (2002) Selective adherence of IgA to murine Peyer’s patch M cells: evidence for a novel IgA receptor. J Immunol 169:1844–1851PubMedGoogle Scholar
  15. 15.
    Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, Calugaru A, Galatiuc C, Regalia T, Tamandl D, Spittler A, Boltz-Nitulescu G (2003) Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol 33:2197–2205PubMedGoogle Scholar
  16. 16.
    Mestecky J, McGhee JR (1987) Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 40:153–245PubMedGoogle Scholar
  17. 17.
    Sangeetha SR, Appukuttan PS (2005) IgA1 is the premier serum glycoprotein recognized by human galectin-1 since T antigen (Galbeta1→3GalNAc−) is far superior to non-repeating N-acetyl lactosamine as ligand. Int J Biol Macromol 35:269–276PubMedGoogle Scholar
  18. 18.
    Rudd PM, Fortune F, Patel T, Parekh RB, Dwek RA, Lehner T (1994) A human T-cell receptor recognizes ‘O’-linked sugars from the hinge region of human IgA1 and IgD. Immunology 83:99–106PubMedGoogle Scholar
  19. 19.
    van Spriel AB, Leusen JH, van Egmond M, Dijkman HB, Assmann KJ, Mayadas TN, van de Winkel JG (2001) Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 97:2478–2486PubMedGoogle Scholar
  20. 20.
    Monteiro RC, Moura IC, Launay P, Tsuge T, Haddad E, Benhamou M, Cooper MD, Arcos-Fajardo M (2002) Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends Mol Med 8:464–468PubMedGoogle Scholar
  21. 21.
    Rifai A, Fadden K, Morrison SL, Chintalacharuvu KR (2000) The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med 191:2171–2182PubMedGoogle Scholar
  22. 22.
    Socken DJ, Underdown BJ (1978) Comparison of human, bovine and rabbit secretory component-immunoglobulin interactions. Immunochemistry 15:499–506PubMedGoogle Scholar
  23. 23.
    Frutiger S, Hughes GJ, Hanly WC, Kingzette M, Jaton JC (1986) The amino-terminal domain of rabbit secretory component is responsible for noncovalent binding to immunoglobulin A dimers. J Biol Chem 261:16673–16681PubMedGoogle Scholar
  24. 24.
    Geneste C, Iscaki S, Mangalo R, Pillot J (1986) Both Fc alpha domains of human IgA are involved in in vitro interaction between secretory component and dimeric IgA. Immunol Lett 13:221–226PubMedGoogle Scholar
  25. 25.
    Fallgreen-Gebauer E, Gebauer W, Bastian A, Kratzin HD, Eiffert H, Zimmermann B, Karas M, Hilschmann N (1993) The covalent linkage of secretory component to IgA. Structure of sIgA. Biol Chem Hoppe Seyler 374:1023–1028PubMedGoogle Scholar
  26. 26.
    Brandtzaeg P (1975) Human secretory immunoglobulin M. An immunochemical and immunohistochemical study. Immunology 29:559–570PubMedGoogle Scholar
  27. 27.
    Mostov KE, Kraehenbuhl JP, Blobel G (1980) Receptor-mediated transcellular transport of immunoglobulin: synthesis of secretory component as multiple and larger transmembrane forms. Proc Natl Acad Sci USA 77:7257–7261PubMedGoogle Scholar
  28. 28.
    Hamburger AE, Bjorkman PJ, Herr AB (2006) Structural insights into antibody-mediated mucosal immunity. Curr Top Microbiol Immunol 308:173–204PubMedGoogle Scholar
  29. 29.
    Lamm ME (1997) Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 51:311–340PubMedGoogle Scholar
  30. 30.
    Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen FE, Nilsen EM, Yamanaka T (1999) Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today 20:141–151PubMedGoogle Scholar
  31. 31.
    Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG (1992) Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 89:6901–6905PubMedGoogle Scholar
  32. 32.
    Kaetzel CS, Robinson JK, Chintalacharuvu KR, Vaerman JP, Lamm ME (1991) The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci USA 88:8796–8800PubMedGoogle Scholar
  33. 33.
    Lamm ME, Robinson JK, Kaetzel CS (1992) Transport of IgA immune complexes across epithelial membranes: new concepts in mucosal immunity. Adv Exp Med Biol 327:91–94PubMedGoogle Scholar
  34. 34.
    Dallas SD, Rolfe RD (1998) Binding of Clostridium difficile toxin A to human milk secretory component. J Med Microbiol 47:879–888PubMedCrossRefGoogle Scholar
  35. 35.
    de Oliveira IR, de Araujo AN, Bao SN, Giugliano LG (2001) Binding of lactoferrin and free secretory component to enterotoxigenic Escherichia coli. FEMS Microbiol Lett 203:29–33PubMedCrossRefGoogle Scholar
  36. 36.
    Hamburger AE, West AP Jr, Bjorkman PJ (2004) Crystal structure of a polymeric immunoglobulin binding fragment of the human polymeric immunoglobulin receptor. Structure 12:1925–1935PubMedGoogle Scholar
  37. 37.
    Coyne RS, Siebrecht M, Peitsch MC, Casanova JE (1994) Mutational analysis of polymeric immunoglobulin receptor/ligand interactions. Evidence for the involvement of multiple complementarity determining region (CDR)-like loops in receptor domain I. J Biol Chem 269:31620–31625PubMedGoogle Scholar
  38. 38.
    White KD, Capra JD (2002) Targeting mucosal sites by polymeric immunoglobulin receptor-directed peptides. J Exp Med 196:551–555PubMedGoogle Scholar
  39. 39.
    Hexham JM, White KD, Carayannopoulos LN, Mandecki W, Brisette R, Yang YS, Capra JD (1999) A human immunoglobulin (Ig)A calpha3 domain motif directs polymeric Ig receptor-mediated secretion. J Exp Med 189:747–752PubMedGoogle Scholar
  40. 40.
    Roe M, Norderhaug IN, Brandtzaeg P, Johansen FE (1999) Fine specificity of ligand-binding domain 1 in the polymeric Ig receptor: importance of the CDR2-containing region for IgM interaction. J Immunol 162:6046–6052PubMedGoogle Scholar
  41. 41.
    Wende H, Colonna M, Ziegler A, Volz A (1999) Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mamm Genome 10:154–160PubMedGoogle Scholar
  42. 42.
    Feng J, Garrity D, Call ME, Moffett H, Wucherpfennig KW (2005) Convergence on a distinctive assembly mechanism by unrelated families of activating immune receptors. Immunity 22:427–438PubMedGoogle Scholar
  43. 43.
    Morton HC, van den Herik-Oudijk IE, Vossebeld P, Snijders A, Verhoeven AJ, Capel PJ, van de Winkel JG (1995) Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR γ chain. Molecular basis for CD89/FcR γ chain association. J Biol Chem 270:29781–29787PubMedGoogle Scholar
  44. 44.
    Cochran JR, Cameron TO, Stone JD, Lubetsky JB, Stern LJ (2001) Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation. J Biol Chem 276:28068–28074PubMedGoogle Scholar
  45. 45.
    Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC (1999) Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem 274:7216–7225PubMedGoogle Scholar
  46. 46.
    Wines BD, Trist HM, Ramsland PA, Hogarth PM (2006) A common site of the Fc receptor gamma subunit interacts with the unrelated immunoreceptors FcalphaRI and FcepsilonRI. J Biol Chem 281:17108–17113PubMedGoogle Scholar
  47. 47.
    Bakema JE, de Haij S, den Hartog-Jager CF, Bakker J, Vidarsson G, van Egmond M, van de Winkel JG, Leusen JH (2006) Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction. J Immunol 176:3603–3610PubMedGoogle Scholar
  48. 48.
    van Zandbergen G, Westerhuis R, Mohamad NK, van de Winkel JG, Daha MR, van Kooten C (1999) Crosslinking of the human Fc receptor for IgA (FcalphaRI/CD89) triggers FcR gamma-chain-dependent shedding of soluble CD89. J Immunol 163:5806–5812PubMedGoogle Scholar
  49. 49.
    Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC (2000) Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med 191:1999–2009PubMedGoogle Scholar
  50. 50.
    Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, Henin D, Benhamou M, Pretolani M, Blank U, Monteiro RC (2005) Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22:31–42PubMedGoogle Scholar
  51. 51.
    Chapman TL, You I, Joseph IM, Bjorkman PJ, Morrison SL, Raghavan M (1999) Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J Biol Chem 274:6911–6919PubMedGoogle Scholar
  52. 52.
    Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO, Wiley DC (1997) Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Nature 389:96–100PubMedGoogle Scholar
  53. 53.
    Horii K, Kahn ML, Herr AB (2006) Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 108:936–942PubMedGoogle Scholar
  54. 54.
    Garman SC, Kinet JP, Jardetzky TS (1998) Crystal structure of the human high-affinity IgE receptor. Cell 95:951–961PubMedGoogle Scholar
  55. 55.
    Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie IF, Garrett TP, Hogarth PM (1999) Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 6:437–442PubMedGoogle Scholar
  56. 56.
    Sondermann P, Huber R, Oosthuizen V, Jacob U (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-FcgammaRIII complex. Nature 406:267–273PubMedGoogle Scholar
  57. 57.
    Sondermann P, Huber R, Jacob U (1999) Crystal structure of the soluble form of the human Fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J 18:1095–1103PubMedGoogle Scholar
  58. 58.
    Herr AB, White CL, Milburn C, Wu C, Bjorkman PJ (2003) Bivalent binding of IgA1 to FcalphaRI suggests a mechanism for cytokine activation of IgA phagocytosis. J Mol Biol 327:645–657PubMedGoogle Scholar
  59. 59.
    Carayannopoulos L, Hexham JM, Capra JD (1996) Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med 183:1579–1586PubMedGoogle Scholar
  60. 60.
    Pleass RJ, Anderson CM, Dunlop JI, Woof JM (1997) Probing the Fc alpha R binding site on IgA by mutagenesis of the IgA Fc region. Biochem Soc Trans 25:328SPubMedGoogle Scholar
  61. 61.
    Pleass RJ, Dunlop JI, Anderson CM, Woof JM (1999) Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89. J Biol Chem 274:23508–23514PubMedGoogle Scholar
  62. 62.
    Wines BD, Hulett MD, Jamieson GP, Trist HM, Spratt JM, Hogarth PM (1999) Identification of residues in the first domain of human Fc alpha receptor essential for interaction with IgA. J Immunol 162:2146–2153PubMedGoogle Scholar
  63. 63.
    Wines BD, Sardjono CT, Trist HM, Lay CS, Hogarth PM (2001) The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster. J Immunol 166:1781–1789PubMedGoogle Scholar
  64. 64.
    Berger J, Hinglais N (1968) [Intercapillary deposits of IgA–IgG]. J Urol Nephrol (Paris) 74:694–695Google Scholar
  65. 65.
    Savoldi S (2001) Berger’s disease. In: F Scolari (ed) Orphanet encyclopedia (updated: January 2004)Google Scholar
  66. 66.
    Berger J, Yaneva H, Nabarra B, Barbanel C (1975) Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int 7:232–241PubMedGoogle Scholar
  67. 67.
    Valentijn RM, Radl J, Haaijman JJ, Vermeer BJ, Weening JJ, Kauffmann RH, Daha MR, van Es LA (1984) Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int 26:760–766PubMedGoogle Scholar
  68. 68.
    Novak J, Julian BA, Tomana M, Mesteck J (2001) Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol 21:310–327PubMedGoogle Scholar
  69. 69.
    Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104:73–81PubMedGoogle Scholar
  70. 70.
    Tomino Y, Sakai H, Miura M, Endoh M, Nomoto Y (1982) Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. Clin Exp Immunol 49:419–425PubMedGoogle Scholar
  71. 71.
    Leung JC, Tang SC, Chan DT, Lui SL, Lai KN (2002) Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy. J Clin Lab Anal 16:11–19PubMedGoogle Scholar
  72. 72.
    Odani H, Hiki Y, Takahashi M, Nishimoto A, Yasuda Y, Iwase H, Shinzato T, Maeda K (2000) Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry. Biochem Biophys Res Commun 271:268–274PubMedGoogle Scholar
  73. 73.
    Linossier MT, Palle S, Berthoux F (2003) Different glycosylation profile of serum IgA1 in IgA nephropathy according to the glomerular basement membrane thickness: normal versus thin. Am J Kidney Dis 41:558–564PubMedGoogle Scholar
  74. 74.
    Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, Coppo R (2001) Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 12:1862–1871PubMedGoogle Scholar
  75. 75.
    Basset C, Devauchelle V, Durand V, Jamin C, Pennec YL, Youinou P, Dueymes M (1999) Glycosylation of immunoglobulin A influences its receptor binding. Scand J Immunol 50:572–579PubMedGoogle Scholar
  76. 76.
    Iwase H, Ohkawa S, Ishii-Karakasa I, Hiki Y, Kokubo T, Sano T, Tanaka A, Toma K, Kobayashi Y, Hotta K (1999) Study of the relationship between sticky human serum IgA1 and its O-glycan glycoform. Biochem Biophys Res Commun 261:472–477PubMedGoogle Scholar
  77. 77.
    Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y (1998) Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 9:2048–2054PubMedGoogle Scholar
  78. 78.
    Sano T, Hiki Y, Kokubo T, Iwase H, Shigematsu H, Kobayashi Y (2002) Enzymatically deglycosylated human IgA1 molecules accumulate and induce inflammatory cell reaction in rat glomeruli. Nephrol Dial Transplant 17:50–56PubMedGoogle Scholar
  79. 79.
    Grossetete B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC (1998) Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int 53:1321–1335PubMedGoogle Scholar
  80. 80.
    van Zandbergen G, van Kooten C, Mohamad NK, Reterink TJ, de Fijter JW, van de Winkel JG, Daha MR (1998) Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant 13:3058–3064PubMedGoogle Scholar
  81. 81.
    Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, Vrtovsnik F, Haddad E, Chintalacharuvu KR, Monteiro RC (2004) Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 15:622–634PubMedGoogle Scholar
  82. 82.
    Merry AH, Gilbert RJ, Shore DA, Royle L, Miroshnychenko O, Vuong M, Wormald MR, Harvey DJ, Dwek RA, Classon BJ, Rudd PM, Davis SJ (2003) O-glycan sialylation and the structure of the stalk-like region of the T cell co-receptor CD8. J Biol Chem 278:27119–27128PubMedGoogle Scholar
  83. 83.
    Monteiro RC, Grossetete B, Nguyen AT, Jungers P, Lehuen A (1995) Dysfunctions of Fc alpha receptors by blood phagocytic cells in IgA nephropathy. Contrib Nephrol 111:116–122PubMedGoogle Scholar
  84. 84.
    Toyabe S, Kuwano Y, Takeda K, Uchiyama M, Abo T (1997) IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells. Clin Exp Immunol 110:226–232PubMedCrossRefGoogle Scholar
  85. 85.
    Barratt J, Greer MR, Pawluczyk IZ, Allen AC, Bailey EM, Buck KS, Feehally J (2000) Identification of a novel Fcalpha receptor expressed by human mesangial cells. Kidney Int 57:1936–1948PubMedGoogle Scholar
  86. 86.
    Westerhuis R, Van Zandbergen G, Verhagen NA, Klar-Mohamad N, Daha MR, van Kooten C (1999) Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). J Am Soc Nephrol 10:770–778PubMedGoogle Scholar
  87. 87.
    Leung JC, Tsang AW, Chan DT, Lai KN (2000) Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol 11:241–249PubMedGoogle Scholar
  88. 88.
    Haddad E, Moura IC, Arcos-Fajardo M, Macher MA, Baudouin V, Alberti C, Loirat C, Monteiro RC, Peuchmaur M (2003) Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch–Schonlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 14:327–337PubMedGoogle Scholar
  89. 89.
    Peebles RS Jr, Hamilton RG, Lichtenstein LM, Schlosberg M, Liu MC, Proud D, Togias A (2001) Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy 31:239–248PubMedGoogle Scholar
  90. 90.
    Nahm DH, Kim HY, Park HS (1998) Elevation of specific immunoglobulin A antibodies to both allergen and bacterial antigen in induced sputum from asthmatics. Eur Respir J 12:540–545PubMedGoogle Scholar
  91. 91.
    Terada N, Terada Y, Shirotori K, Ishikawa K, Togawa K, Konno A (1996) Immunoglobulin as an eosinophil degranulation factor: change in immunoglobulin level in nasal lavage fluid after antigen challenge. Acta Otolaryngol 116:863–867PubMedGoogle Scholar
  92. 92.
    Peebles RS Jr, Liu MC, Lichtenstein LM, Hamilton RG (1995) IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays. J Immunol Methods 179:77–86PubMedGoogle Scholar
  93. 93.
    Iikura M, Yamaguchi M, Fujisawa T, Miyamasu M, Takaishi T, Morita Y, Iwase T, Moro I, Yamamoto K, Hirai K (1998) Secretory IgA induces degranulation of IL-3-primed basophils. J Immunol 161:1510–1515PubMedGoogle Scholar
  94. 94.
    Seminario MC, Gleich GJ (1994) The role of eosinophils in the pathogenesis of asthma. Curr Opin Immunol 6:860–864PubMedGoogle Scholar
  95. 95.
    Pleass RJ, Lang ML, Kerr MA, Woof JM (2006) IgA is a more potent inducer of NADPH oxidase activation and degranulation in blood eosinophils than IgE. Mol Immunol 1401–1408Google Scholar
  96. 96.
    Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ (1989) IgA-induced eosinophil degranulation. J Immunol 142:2393–2400PubMedGoogle Scholar
  97. 97.
    Pilette C, Durham SR, Vaerman JP, Sibille Y (2004) Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc 1:125–135PubMedGoogle Scholar
  98. 98.
    Ludviksson BR, Eiriksson TH, Ardal B, Sigfusson A, Valdimarsson H (1992) Correlation between serum immunoglobulin A concentrations and allergic manifestations in infants. J Pediatr 121:23–27PubMedGoogle Scholar
  99. 99.
    Schwarze J, Cieslewicz G, Joetham A, Sun LK, Sun WN, Chang TW, Hamelmann E, Gelfand EW (1998) Antigen-specific immunoglobulin-A prevents increased airway responsiveness and lung eosinophilia after airway challenge in sensitized mice. Am J Respir Crit Care Med 158:519–525PubMedGoogle Scholar
  100. 100.
    Montenegro V, Monteiro RC (1999) Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Curr Opin Rheumatol 11:265–272PubMedGoogle Scholar
  101. 101.
    Veys EM, van Leare M (1973) Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis 32:493–496PubMedCrossRefGoogle Scholar
  102. 102.
    Feltelius N, Hvatum M, Brandtzaeg P, Knutson L, Hallgren R (1994) Increased jejunal secretory IgA and IgM in ankylosing spondylitis: normalization after treatment with sulfasalazine. J Rheumatol 21:2076–2081PubMedGoogle Scholar
  103. 103.
    Hunter T, Harding GK, Kaprove RE, Schroeder ML (1981) Fecal carriage of various Klebsiella and Enterobacter species in patients with active ankylosing spondylitis. Arthritis Rheum 24:106–108PubMedGoogle Scholar
  104. 104.
    Montenegro V, Chiamolera M, Launay P, Goncalves CR, Monteiro RC (2000) Impaired expression of IgA Fc receptors (CD89) by blood phagocytic cells in ankylosing spondylitis. J Rheumatol 27:411–417PubMedGoogle Scholar
  105. 105.
    Brandtzaeg P (2006) The changing immunological paradigm in coeliac disease. Immunol Lett 105:127–139PubMedGoogle Scholar
  106. 106.
    Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity. J Pathol 208:270–282PubMedGoogle Scholar
  107. 107.
    Fry L (2002) Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol 12:523–531PubMedGoogle Scholar
  108. 108.
    Collin P, Maki M, Keyrilainen O, Hallstrom O, Reunala T, Pasternack A (1992) Selective IgA deficiency and coeliac disease. Scand J Gastroenterol 27:367–371PubMedGoogle Scholar
  109. 109.
    Silvain C, Patry C, Launay P, Lehuen A, Monteiro RC (1995) Altered expression of monocyte IgA Fc receptors is associated with defective endocytosis in patients with alcoholic cirrhosis. Potential role for IFN-gamma. J Immunol 155:1606–1618PubMedGoogle Scholar
  110. 110.
    Basset C, Durand V, Jamin C, Clement J, Pennec Y, Youinou P, Dueymes M, Roitt IM (2000) Increased N-linked glycosylation leading to oversialylation of monomeric immunoglobulin A1 from patients with Sjogren’s syndrome. Scand J Immunol 51:300–306PubMedGoogle Scholar
  111. 111.
    Saulsbury FT (2001) Henoch–Schonlein purpura. Curr Opin Rheumatol 13:35–40PubMedGoogle Scholar
  112. 112.
    Saulsbury FT (1997) Alterations in the O-linked glycosylation of IgA1 in children with Henoch–Schonlein purpura. J Rheumatol 24:2246–2249PubMedGoogle Scholar
  113. 113.
    Allen AC, Willis FR, Beattie TJ, Feehally J (1998) Abnormal IgA glycosylation in Henoch–Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 13:930–934PubMedGoogle Scholar
  114. 114.
    Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy. Immunol Today 21:403–410PubMedGoogle Scholar
  115. 115.
    von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343–369Google Scholar
  116. 116.
    Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG (1997) FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90:4485–4492PubMedGoogle Scholar
  117. 117.
    Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, Logtenberg T (1999) Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res 59:5778–5784PubMedGoogle Scholar
  118. 118.
    Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, van de Winkel JG, van Egmond M (2005) Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 174:5472–5480PubMedGoogle Scholar
  119. 119.
    Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van de Winkel JG, Valerius T (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100:4574–4580PubMedGoogle Scholar
  120. 120.
    Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148–158PubMedGoogle Scholar
  121. 121.
    Niedergang F, Kweon MN (2005) New trends in antigen uptake in the gut mucosa. Trends Microbiol 13:485–490PubMedGoogle Scholar
  122. 122.
    Ogra PL (2003) Mucosal immunity: some historical perspective on host–pathogen interactions and implications for mucosal vaccines. Immunol Cell Biol 81:23–33PubMedGoogle Scholar
  123. 123.
    Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH (1991) Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 163:1–6PubMedGoogle Scholar
  124. 124.
    Tamura S, Kurata H, Funato H, Nagamine T, Aizawa C, Kurata T (1989) Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit. Vaccine 7:314–320PubMedGoogle Scholar
  125. 125.
    Corthesy B, Kaufmann M, Phalipon A, Peitsch M, Neutra MR, Kraehenbuhl JP (1996) A pathogen-specific epitope inserted into recombinant secretory immunoglobulin A is immunogenic by the oral route. J Biol Chem 271:33670–33677PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Molecular Genetics, Biochemistry and MicrobiologyCollege of Medicine, University of CincinnatiCincinnatiUSA

Personalised recommendations